| Literature DB >> 31245165 |
Maciej Ciesielski1,2, Wiesław Janusz Kruszewski1,2, Mariusz Szajewski1,2, Jakub Walczak1, Natalia Spychalska1, Jarosław Szefel1,2, Jacek Zieliński3.
Abstract
PURPOSE: Poor physiological reserve for withstanding major cancer surgery in older adults is an important concern in the selection of patients for oncologic gastrectomy. The present study aimed to analyze mortality patterns among patients who underwent gastrectomy for cancer according to age groups. The primary outcomes of this study were early- and middle-term results: 30-day and 3-, 6-, 12-, and 36-month mortality rates.Entities:
Keywords: Aged; Gastrectomy; Geriatrics; Mortality; Stomach neoplasms
Year: 2019 PMID: 31245165 PMCID: PMC6589425 DOI: 10.5230/jgc.2019.19.e16
Source DB: PubMed Journal: J Gastric Cancer ISSN: 1598-1320 Impact factor: 3.720
Fig. 1Mortality rates according to age subgroups.
Mortality rates in the four groups of patients
| Group | No. | 30-day mortality (%) | 3-month mortality (%) | 6-month mortality (%) | 12-month mortality (%) | 36-month mortality (%) |
|---|---|---|---|---|---|---|
| I | 28 | 0 | 3.6 | 14.3 | 25.0 | 60.7 |
| II | 119 | 0.8 | 5.0 | 8.4 | 16.0 | 41.2 |
| III | 83 | 7.2 | 12.0 | 16.9 | 28.9 | 59.0 |
| IV | 58 | 12.1 | 17.2 | 29.3 | 41.4 | 69.0 |
Fig. 2Overall survival in the four groups of patients in terms of age (P<0.001).
Results of the statistical comparison of mortality rates
| Mortality rate | P-value | |||
|---|---|---|---|---|
| Group I vs. Group II | Group II vs. Group III | Group III vs. Group IV | Group II vs. Group IV | |
| 30-day | 0.63 | 0.01 | 0.32 | <0.001 |
| 3-mo | 0.74 | 0.06 | 0.37 | 0.008 |
| 6-mo | 0.34 | 0.06 | 0.07 | <0.001 |
| 12-mo | 0.25 | 0.02 | 0.09 | <0.001 |
| 36-mo | 0.06 | 0.009 | 0.11 | <0.001 |
Fig. 3(A) Comparison of the 5-year survival of group I and patients aged between 51 and 55 years (P=0.09). (B) Comparison of the 3-year survival of group I and patients aged between 51 and 55 years (P=0.02).
Pathological variables in the groups classified according to age
| Variables | Group I | P-value (Group I vs. Group II) | Group II | P-value (Group II vs. Group IV) | Group IV |
|---|---|---|---|---|---|
| Infiltration of the serosa (pT4; %) | 28.6 | 0.32 | 38.7 | 0.15 | 27.6 |
| Nodal involvement (pN1-pN3; %) | 71.4 | 0.79 | 68.9 | 0.01 | 50.0 |
| Mean/median metastatic nodes | 6.8/2.5 | 0.94 | 6.4/3 | 0.009 | 3.8/1 |
| Mean (median) total number of resected lymph nodes | 21.8 (21.5) | 0.59 | 21.1 (19) | 0.02 | 17.2 (14.5) |
| Extend of lymphadenectomy, ≥D2 (%) | 21.4 | 0.64 | 17.6 | 0.02 | 5.1 |
| Lauren diffused and mixed type (%) | 42.9 | 0.23 | 55.5 | 0.12 | 43.1 |
| Cardia involvement (%) | 67.9 | 0.51 | 74.0 | 0.83 | 72.4 |
| Distant metastases (M1; %) | 10.7 | 0.97 | 10.9 | 0.82 | 12.1 |
| pTNM III–IV (%) | 53.6 | 0.95 | 52.9 | 0.22 | 43.1 |
| Morbidity rate (%) | 25.0 | 0.38 | 16.7 | 0.01 | 35.6 |
| Neoadjuvant chemotherapy (%) | 15.0 | 0.47 | 9.5 | 0.3 | 4.4 |
Impact of postoperative morbidity on mortality periods in 141 patients aged over 65 years
| Mortality period | No. of patients (%) | |
|---|---|---|
| Mortality rate | Morbidity rate | |
| 0–30 day | 13/141 (9.2) | 13/13 (100) |
| 31 day–6 mo | 18/141 (12.8) | 6/18 (33.3) |
| 7–12 mo | 17/141 (12.1) | 4/17 (23.5) |
| 1-yr survival | 93/141 (66.0) | 15/93 (16.1) |
Clinicopathologic characteristics of patients who did not present with any complications and who died between 1 and 6 months after surgery
| Patient | Sex/age | pTNM | Procedure | Radical/palliative intent | Day of discharge (since surgery) | Survival (mo) | Cancer relapse (yes/no) |
|---|---|---|---|---|---|---|---|
| 1 | M/66 | pT4aN3bM0 | Gastrectomy D1+ | Curative | 8 | 5 | Yes |
| 2 | M/69 | pT3N0M0 | Gastrectomy D1 | Curative | 8 | 5 | No |
| 3 | F/70 | pT4aN3aM0 | Gastrectomy D1 | Curative | 8 | 2 | No |
| 4 | M/70 | pT3N3aM0 | Gastrectomy D2 | Curative | 12 | 5 | Yes |
| 5 | M/71 | pT2N1M0 | Gastrectomy D2 | Curative | 14 | 2 | No |
| 6 | F/71 | pT3N2M0 | Subtotal resection D1 | Palliative | 7 | 2 | No |
| 7 | F/71 | pT4aNxM0 | Subtotal resection D0 | Palliative | 5 | 4 | Yes |
| 8 | F/77 | pT2N2M0 | Gastrectomy D1 | Curative | 9 | 3 | No |
| 9 | M/79 | pT3N3bM0 | Gastrectomy D1 | Palliative | 10 | 2 | No |
| 10 | M/80 | pT4aN0M0 | Gastrectomy D1 | Curative | 10 | 1 | No |
| 11 | M/81 | pT3N2M0 | Gastrectomy D1 | Curative | 11 | 4 | No |
| 12 | F/84 | pT4aN3bM0 | Gastrectomy D2 | Curative | 8 | 3 | No |
Fig. 4Comparison of the overall survival of patients who lived at least 12 months after gastric resection in groups II and IV (P=0.16).